Filing Flows › Lifecore Biomedical (LFCR) › Q4 FY25
Lifecore Biomedical (LFCR) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Aug 7, 2025
Lifecore Biomedical (LFCR) reported revenue of $36.4M for the fourth quarter fiscal 2025 (Q4 FY25), -4% from a year earlier and +4% from the quarter before. Operating margin was 14.6%, net loss $1.1M (3.1% of revenue).
Lifecore Biomedical, Q4 FY25: revenue $36.4M (-4% year over year), operating margin 14.6%, net loss $1.1M, operating cash flow $5.3M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $36.4M | +4% | -4% |
| Operating profit | $5.3M | — | — |
| Net earnings | −$1.1M | — | — |
| Operating cash flow | $5.3M | +346% | -39% |
| Free cash flow | $3.2M | — | -46% |
What changed
Revenue was $36.4M in Q4 FY25, down 4% year over year and up 4% from the previous quarter. CDMO was the largest line at 65% of revenue.
Gross margin was 38.4%, down 7.2 points from a year earlier. Operating profit was $5.3M, a 14.6% margin (up 8.9 points year over year). Operating expenses fell 43% while revenue fell 4%. The quarter ended with a net loss of $1.1M, narrower than the previous quarter's $14.8M loss. Net interest and other expense of $6.4M was the main reason.
Operating cash flow was $5.3M (down 39% year over year). Non-cash charges added back $1.9M of depreciation and $1.8M of share-based compensation. Working capital and other items added $2.8M. Capital expenditures of $2.1M left free cash flow of $3.2M.
Questions
What was Lifecore Biomedical's revenue in the fourth quarter fiscal 2025?
Lifecore Biomedical (LFCR) reported revenue of $36.4M for the fourth quarter fiscal 2025 (Q4 FY25), -4% from a year earlier and +4% from the quarter before.
Was Lifecore Biomedical profitable in the fourth quarter fiscal 2025?
Operating profit was $5.3M (14.6% of revenue) and net loss $1.1M.